Merck Becomes Member of the Worldwide Innovative Network in Personalized Cancer Medicine
Posted: Thursday, June 15, 2017
June 15, 2017 06:00 AM Eastern Daylight Time
PARIS & DARMSTADT, Germany--(BUSINESS WIRE)--Worldwide Innovative Network in Personalized Cancer Medicine - WIN Consortium proudly announces today that Merck, which operates its biopharmaceutical business as EMD Serono in the U.S. and Canada, becomes a member of the WIN Consortium. WIN is a network of 40 academic institutions and industries across the globe, focusing on new generation biomarker-driven therapeutic clinical trials and biomarker discovery programs conducted worldwide, aiming to significantly impact the survival of cancer patients. Merck reinforces WIN’s pharmaceutical industry membership. WIN’s global collaborative research strategy will be presented at the WIN 2017 Symposium in Paris, France, on 26-27 June.
Merck’s strong corporate commitment to the development of drugs using a precision medicine approach, coupled with the company’s wide breadth of experience in the development of oncology therapeutics, its company’s goals and capabilities are strategically aligned with the mission of WIN.
"Bringing the latest advances in personalized cancer medicine to the patient requires collaboration and partnerships between multiple sectors of the health sciences community,” said Dr. John Mendelsohn, Chairman of WIN. “ Merck's strong commitment to the development of targeted cancer therapeutics and its breadth of expertise in oncology drug development will play a key role in accelerating the pace at which patients can benefit from advances in personalized cancer medicine. We are proud to have Merck and Pfizer Inc. as WIN's pharmaceutical partners and believe that this collaboration will benefit cancer patients worldwide." said Dr. Vladimir Lazar, Chief Scientific and Operating Officer of WIN.
The WIN Consortium is a global network of 40 leading organizations from the academic, pharmaceutical, biotechnology and patient advocacy sectors working to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials, the most promising advances in genomic-based cancer research. WIN is a non-governmental, not-for-profit organization headquartered in Paris.
For further information, please visit www.winconsortium.org.
Director Operational Team
Vladimir Lazar, Tel: + 33 66 109 15 22
Chief Scientific and Operating Officer
Diversity of Stakeholders - WIN Members
Studies with a global population
Sharing information to promote use of personalized, targeted cancer therapy: WIN Symposia
WIN was created to accelerate the pace and reduce the cost of translating novel cancer treatments to the bedside by developing and applying, through worldwide clinical trials and research projects, the most promising advances in genomic-based cancer research. WIN aims to initiate research projects each year in a global consortium guided by an independent scientific advisory board.
WIN now includes 40 institutional members. These stakeholders have come together from all parts of the world to address the challenge of increasing the efficacy of cancer diagnostics and therapeutics by understanding the genetics and biology of each individual’s tumor and accounting for genetic differences across diverse populations—from North and South America, Europe, Asia, and the Middle East.
Our goal is to significantly improve outcomes for patients around the globe. We aim to increase the number of patients worldwide that have access to innovative, global clinical trials in the area of genomic-based cancer therapeutics. Global diversity and inclusion of all stakeholders is WIN’s most important and differentiating asset.
Our members include leading academic, pharmaceutical, life science, not-for-profit, health IT, and healthpayer organizations.
WIN's first trial, WINTHER, is currently being carried out through a collaboration between six academic centers in five countries, with key support from Europe (EUFP7), Fondation ARC, Pfizer and other pharma companies.